Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635557 | 0.93 | — | — | |
| SCHEMBL4724577 | 0.88 | ADH1A (0.32) | NOS3NOS1NOS2 | |
| SCHEMBL4721340 | 0.85 | CYP1A2 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL4722799 | 0.83 | ADH1A (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL4720623 | 0.81 | — | — | |
| SCHEMBL4722161 | 0.80 | NOS3 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL4723246 | 0.79 | CYP1A2 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL4765143 | 0.78 | — | — | |
| SCHEMBL9432432 | 0.77 | GBA1 (0.38) | NOS3NOS1NOS2 | |
| SCHEMBL4722020 | 0.77 | CYP1A2 (0.31) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049536-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-22 | — | — | EP | claimed |
| US-20080234284-A1 | Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2008-09-25 | — | — | US | claimed |
| EP-1910368-A1 | PYRAZOLO[1.5-A]PYRIMIDIN-7-YL AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2008-04-16 | — | — | EP | claimed |
| WO-2008011521-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| WO-2007009773-A1 | PYRAZOLO[1.5-A]PYRIMIDIN-7-YL AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | claimed |
| US-7834015-B2 | treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV skin damage, and as chemosensitizers or radiosensitizers for cancer treatment | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-11-16 | — | — | US | disclosed |
| US-20090209523-A1 | Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-08-20 | — | — | US | disclosed |
| EP-2032140-A1 | PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-03-11 | — | — | EP | disclosed |
| US-20080234284-A1 | Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2008-09-25 | — | — | US | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1910368-A1 | PYRAZOLO[1.5-A]PYRIMIDIN-7-YL AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007138355-A1 | PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007009773-A1 | PYRAZOLO[1.5-A]PYRIMIDIN-7-YL AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-28 | — | — | US | disclosed |
| WO-1995015955-A1 | 2,4-DIAMINOTHIAZOLES AND THEIR PRODUCTION | BASF AKTIENGESELLSCHAFT (DE) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | NOS3 1350/4885NOS1 2886/4885NOS2 2693/4885 |
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | SLC10A6, SLC7A1, SLC10A1 | NOS3 2912/4885NOS1 2956/4885NOS2 2804/4885 |
| US-20080234284-A1 | Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors | MAP3K5, MAP3K20, MAP3K7 | NOS3 1601/4885NOS1 1271/4885NOS2 1492/4885 |
| US-20090209523-A1 | Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) | PARP1, PARP2, PARP11 | NOS3 3957/4885NOS1 3478/4885NOS2 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.